- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00001024
The Effects of Anti-HIV Drugs in HIV-Infected Patients Who Do Not Have AIDS
A Multicenter, Open-Label Study of Viral Burden in Peripheral Blood Versus Lymphoid Tissue Before and After Antiretroviral Therapy in HIV-Infected Individuals Without AIDS (NOTE: One Arm Receives no Treatment)
Immunopathogenesis objectives: To compare and quantitatively determine HIV burden and HIV replication in peripheral blood (PB) and lymphoid tissue (LT). To determine the degree to which antiretroviral therapy alters HIV replication in LT.
Clinical objectives: To gain insight into the degree of correlation between immunologic surrogate markers for HIV disease (e.g., CD4, beta-2 microglobulin) as compared to measures of HIV replication in PB and LT. To assess changes in PB and LT viral burden after antiretroviral therapy and to determine its ability to predict an antiviral response.
One of the major problems in defining the immunopathogenic changes in HIV infections has been the inability to correlate the extent of loss of immunologic function with the number of HIV-infected CD4+ cells in the peripheral blood. Few studies exist that measure viral burden in lymph nodes of HIV-infected individuals. Researchers hope to find out whether the amount of HIV virus or markers for the virus in the body's lymph tissue is a better measure of disease progression than the amount of virus or markers for the virus in the blood.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
One of the major problems in defining the immunopathogenic changes in HIV infections has been the inability to correlate the extent of loss of immunologic function with the number of HIV-infected CD4+ cells in the peripheral blood. Few studies exist that measure viral burden in lymph nodes of HIV-infected individuals. Researchers hope to find out whether the amount of HIV virus or markers for the virus in the body's lymph tissue is a better measure of disease progression than the amount of virus or markers for the virus in the blood.
Sixteen antiretroviral-naive patients are randomized to either remain antiretroviral-naive (no treatment) or receive zidovudine daily (treatment). Additionally, 16 patients with 26 or more weeks of ongoing zidovudine (AZT) therapy are randomized to either continue on their prestudy AZT regimen or add didanosine (ddI) daily to their baseline AZT dose. Patients remain on their assigned treatment arms for 8 weeks. A lymph node biopsy is performed on day 0 and at week 8. Patients are evaluated at weeks 2, 4, 6, 8 and 9.
Studientyp
Einschreibung
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
California
-
Palo Alto, California, Vereinigte Staaten, 94304
- Palo Alto Veterans Affairs Health Care System
-
San Francisco, California, Vereinigte Staaten, 94115
- Kaiser Permanente Med Ctr
-
San Francisco, California, Vereinigte Staaten, 94115
- Mount Zion Med Ctr / UCSF
-
-
Illinois
-
Chicago, Illinois, Vereinigte Staaten, 60612
- Univ of Illinois
-
-
Maryland
-
Baltimore, Maryland, Vereinigte Staaten, 21201
- Univ of Maryland at Baltimore
-
-
New York
-
Stony Brook, New York, Vereinigte Staaten, 117948153
- SUNY / Health Sciences Ctr at Stony Brook
-
-
North Carolina
-
Durham, North Carolina, Vereinigte Staaten, 27710
- Duke Univ Med Ctr
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15261
- Univ of Pittsburgh
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria
Concurrent Medication:
Allowed:
- Chemoprophylaxis against M. tuberculosis, therapy for oral candidiasis, and short courses (up to 10 days) of acyclovir for herpes lesions.
- Antibiotics as clinically indicated.
- Pneumococcal vaccine and hepatitis B vaccine as medically indicated.
- Regularly prescribed medications such as antipyretics, analgesics, allergy medications, antidepressants, sleep medications, oral contraceptives, or other medications deemed appropriate by the patient's primary care provider.
Recommended:
- PCP prophylaxis if patient's CD4 count falls below 200 cells/mm3 during the study.
Concurrent Treatment:
Allowed:
- Alternative therapies such as vitamins and acupuncture.
Patients must have:
- Documented HIV infection.
- At least two palpable lymph nodes above the waist.
- CD4 counts >= 350 cells/mm3 (if previously antiretroviral-naive) or >= 250 cells/mm3 (if receiving ongoing AZT therapy).
Patients with prior AZT therapy must have received a stable dose of 300-600 mg daily for 26 or more weeks.
Prior Medication:
Required in patients with prior ongoing therapy:
- AZT at dose of 300-600 mg daily for at least 26 weeks.
Exclusion Criteria
Co-existing Condition:
Patients with the following symptoms and conditions are excluded:
- Severe malabsorption.
- Current AIDS-related opportunistic infection, AIDS dementia, AIDS-wasting syndrome, or an AIDS-related malignancy other than minimal Kaposi's sarcoma disease.
- Current medical problems that may interfere with the evaluation of AZT or increase the potential toxicity of AZT (e.g., significant liver disease, diabetes, significant cardiovascular disease, seizure disorders, lymphoma, acute or chronic pancreatitis, or febrile illness).
- Current diagnosis of malignancy for which systemic therapy would be required during study.
Concurrent Medication:
Excluded:
- Ganciclovir, foscarnet, chronic acyclovir, or probenecid.
- Other proven or alleged antiretroviral or anti-HIV drugs.
- Biologic response modifiers.
- Valproic acid.
- Systemic cytotoxic chemotherapy.
- Steroids.
Concurrent Treatment:
Excluded:
- Radiation therapy.
Patients with the following prior conditions are excluded:
- Prior AIDS-related opportunistic infection, AIDS dementia, AIDS-wasting syndrome, or an AIDS-related malignancy other than minimal Kaposi's sarcoma disease.
- History of medical problems that may interfere with the evaluation of AZT or increase the potential toxicity of AZT (e.g., significant liver disease, diabetes, significant cardiovascular disease, seizure disorders, lymphoma, acute or chronic pancreatitis, or febrile illness).
- History of peripheral neuropathy (patients with prior AZT treatment only).
Prior Medication:
Excluded:
- Prior ddI therapy.
- Less than 26 weeks of prior AZT (in patients with ongoing AZT therapy only).
- Ganciclovir, foscarnet, chronic acyclovir, or probenecid.
- Cytotoxic chemotherapy within 1 month prior to study entry.
- Acute therapy for an infection or other medical illness within 14 days prior to study entry.
History of alcohol abuse (patients with prior AZT treatment).
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
Mitarbeiter und Ermittler
Ermittler
- Studienstuhl: M Niu
- Studienstuhl: J Cohn
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Cohen OJ, Pantaleo G, Graziosi C, Niu M, Fauci AS. Effect of antiretroviral therapy on HIV burden and replication in lymphoid tissue. DATRI 003 Study Group. Int Conf AIDS. 1994 Aug 7-12;10(1):7 (abstract no 001B)
Studienaufzeichnungsdaten
Haupttermine studieren
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- RNA-Virusinfektionen
- Viruserkrankungen
- Infektionen
- Durch Blut übertragene Infektionen
- Übertragbare Krankheiten
- Sexuell übertragbare Krankheiten, viral
- Sexuell übertragbare Krankheiten
- Lentivirus-Infektionen
- Retroviridae-Infektionen
- Immunologische Mangelsyndrome
- Erkrankungen des Immunsystems
- HIV-Infektionen
- Molekulare Mechanismen der pharmakologischen Wirkung
- Antiinfektiva
- Antivirale Mittel
- Reverse-Transkriptase-Inhibitoren
- Inhibitoren der Nukleinsäuresynthese
- Enzym-Inhibitoren
- Anti-HIV-Agenten
- Antiretrovirale Mittel
- Antimetaboliten
- Zidovudin
- Didanosin
Andere Studien-ID-Nummern
- DATRI 003
- 11734 (Registrierungskennung: DAIDS ES Registry Number)
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur HIV-Infektionen
-
Duke UniversityAbgeschlossenCentral Line-associated Bloodstream Infection (CLABSI)Vereinigte Staaten
-
Catholic University of the Sacred HeartAbgeschlossenCentral Line-associated Bloodstream Infection (CLABSI)
-
Abbott Medical DevicesThoratec CorporationAbgeschlossenDriveline Heart-assisted Device Related InfectionVereinigte Staaten
-
Princess Maxima Center for Pediatric OncologyUMC Utrecht; Dutch Cancer SocietyRekrutierungCentral Line-associated Bloodstream Infection (CLABSI)Niederlande
-
University of MalayaTeleflexRekrutierungCLABSI – Central Line Associated Bloodstream InfectionMalaysia
-
National Taiwan University Hospital Hsin-Chu BranchAbgeschlossenCentral Line-associated Bloodstream Infection (CLABSI)
-
Johns Hopkins UniversityAbgeschlossenCLABSI – Central Line Associated Bloodstream InfectionVereinigte Staaten
-
National Taiwan University HospitalAbgeschlossenCentral Line-associated Bloodstream Infection (CLABSI)Taiwan
-
University of ZurichNoch keine RekrutierungCentral Line-associated Bloodstream Infection (CLABSI) | Katheterbedingte Blutstrominfektion
-
Princess Anna Mazowiecka Hospital, Warsaw, PolandNutricia FoundationAktiv, nicht rekrutierendWachstumsfehler | CLABSI – Central Line Associated Bloodstream InfectionPolen
Klinische Studien zur Zidovudin
-
Glaxo WellcomeUnbekanntHIV-InfektionenVereinigte Staaten
-
Glaxo WellcomeAbgeschlossenHIV-InfektionenVereinigte Staaten, Puerto Rico
-
Institut de Recherche pour le DeveloppementEunice Kennedy Shriver National Institute of Child Health and Human Development... und andere MitarbeiterAbgeschlossenHIV-Infektionen | SchwangerschaftThailand
-
National Institute of Allergy and Infectious Diseases...Eunice Kennedy Shriver National Institute of Child Health and Human Development...AbgeschlossenHIV-InfektionenVereinigte Staaten, Puerto Rico
-
Glaxo WellcomeAbgeschlossenHIV-InfektionenVereinigte Staaten
-
Glaxo WellcomeAbgeschlossenHIV-Infektionen | LipodystrophieVereinigte Staaten
-
ViiV HealthcareAbgeschlossen
-
Universidad Peruana Cayetano HerediaMerck Sharp & Dohme LLCAbgeschlossenHTLV-I-Infektionen | Tropische spastische ParaparesePeru
-
University of Colorado, DenverNational Institute of Allergy and Infectious Diseases (NIAID); University of...Abgeschlossen
-
National Institute of Allergy and Infectious Diseases...Eunice Kennedy Shriver National Institute of Child Health and Human Development...AbgeschlossenHIV-InfektionenVereinigte Staaten, Puerto Rico